Skip to main content
. 2024 Feb 21;14(2):e077408. doi: 10.1136/bmjopen-2023-077408

Figure 2.

Figure 2

Risk of infection, hospitalisation and death associated with immunosuppressive exposure from January 2021 to November 2021 in inflammatory bowel disease (IBD), arthropathy, psoriasis and across all immune-mediated inflammatory diseases (IMID) cohorts.